Piper Brian 4

4 · Sana Biotechnology, Inc. · Filed Feb 18, 2026

AI-generated summary of this filing

Updated Feb 18, 2026

Sana (SANA) CFO Brian Piper Receives 1.1M RSU/Option Awards

What Happened

Brian Piper, Chief Financial Officer of Sana Biotechnology (SANA), was granted two derivative awards on February 17, 2026 totaling 1,100,000 units: 200,000 restricted stock units (RSUs) and 900,000 additional award units. Both awards show an acquisition price of $0.00 (i.e., no cash paid by the insider).
Per the filing footnotes, each RSU is a contingent right to receive one share of common stock on vesting. The 200k RSUs vest in four equal annual installments on Feb 17 of 2027, 2028, 2029 and 2030. The 900k award vests 25% on Feb 17, 2027 and then in 36 equal monthly installments thereafter.

Key Details

Transaction date: 2026-02-17; Form 4 filed: 2026-02-18 (timely filing).
Grants: 200,000 RSUs @ $0.00; 900,000 derivative award units @ $0.00 (total = 1,100,000 units).
Vesting: 200k RSUs — four equal annual installments (Feb 17, 2027–2030). 900k award — 25% on Feb 17, 2027 then 36 monthly installments (per footnote).
Shares owned after transaction: not specified in the provided excerpt of the filing.
Transaction code: A = Award/Grant. No indication of 10b5-1 plan, tax withholding, cashless sale, or gift in the provided notes.

Context

These are compensation/retention awards (not open-market purchases or sales). RSUs are rights to receive shares upon vesting; the 900k award follows a common executive vesting schedule (one-year cliff then monthly vesting). Such grants are typical for newly hired or retained executives and do not by themselves indicate current buying or selling sentiment.

Form 4

Period: 2026-02-17

EVP, Chief Financial Officer

Transactions

Award
Restricted Stock Units
[F1][F2]
2026-02-17+200,000→ 200,000 total
→ Common Stock (200,000 underlying)
Award
Stock Option (Right to Buy)
[F3]
2026-02-17+900,000→ 900,000 total
Exercise: $3.85Exp: 2036-02-16→ Common Stock (900,000 underlying)

Footnotes (3)

[F1]Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.
[F2]The restricted stock units vest in four equal installments on each of February 17, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
[F3]The option vests and becomes exercisable as to 25% of the underlying shares on February 17, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

Signature

/s/ Aaron M. Grossman, Attorney-in-Fact for Brian Piper|2026-02-18

1 file